Although therapeutic targeting of AKT could provide pro-apoptotic cancer therapy (Bailey et al, 2006; Chee et al, 2007; Yap et al, 2008), effects of small interfering RNA (siRNA) knockdown of AKT on apoptosis are inconsistent (Koseoglu et al, 2007) and results from recent phase I and II clinical trials of AKT inhibitor monotherapy have been disappointing (Argiris et al, 2006; Yap et al, 2008; Gills and Dennis, 2009). The gene discussed is AKT1; the disease is cancer.